Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Debt (2016 - 2023)

Amicus Therapeutics' Total Debt history spans 14 years, with the latest figure at $13.0 million for Q2 2023.

  • For the quarter ending Q2 2023, Total Debt fell 32.5% year-over-year to $13.0 million, compared with a TTM value of $13.0 million through Jun 2023, down 32.5%, and an annual FY2022 reading of $21.4 million, up 13.32% over the prior year.
  • Total Debt for Q2 2023 was $13.0 million at Amicus Therapeutics, up from $12.7 million in the prior quarter.
  • The five-year high for Total Debt was $147.8 million in Q2 2020, with the low at $8.9 million in Q4 2020.
  • Average Total Debt over 5 years is $63.1 million, with a median of $19.8 million recorded in 2021.
  • Year-over-year, Total Debt skyrocketed 1609.23% in 2019 and then crashed 93.96% in 2020.
  • Tracing FOLD's Total Debt over 5 years: stood at $147.4 million in 2019, then crashed by 93.96% to $8.9 million in 2020, then skyrocketed by 112.36% to $18.9 million in 2021, then rose by 13.32% to $21.4 million in 2022, then tumbled by 39.28% to $13.0 million in 2023.
  • Per Business Quant, the three most recent readings for FOLD's Total Debt are $13.0 million (Q2 2023), $12.7 million (Q1 2023), and $21.4 million (Q4 2022).